Search results
Jan 23, 2018 · Zacks Equity Research. Updated Tue, Jan 23, 2018, 9:36 AM. Celgene Corporation CELG announced that it will acquire Juno Therapeutics, Inc. JUNO for $87 per share in cash, or a total of ...
Feb 1, 2019 · Abstract. Background: Adoptive T-cell therapy with engineered T-cell receptors (eTCR) has demonstrated promising, yet modest clinical benefit to date. Key obstacles for this technology are 1) competition with the endogenous TCR for CD3 components that are required for surface expression of a functional TCR complex and 2) mispairing of endogenous and exogenous TCRα and TCRβ chains. Substituting murine TCR constant domains has been shown to enhance eTCR expression, but increases the risk of ...
On February 5, 2021, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for the treatment of adult patients with relapsed or refractory (R/R ...
Juno Therapeutics $111.87 m in annual revenue in FY 2017. See insights on Juno Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.
Jan 22, 2018 · Celgene Corp. will acquire Juno Therapeutics Inc. and its pipeline of cancer cell therapies for $9 billion, betting on the continued emergence of CAR-T at a time when concerns over future growth have shaken investor confidence in the blue chip biotech. At a takeout price of $87 per share, the deal values Juno at a nearly 91% premium to the ...
Recently, Juno Therapeutics embarked on a project to combine their multiple locations into one headquarter location. Juno and Flad Architects engaged Studio Other and Tangram Technology for custom workspace and technology integration throughout the nine floors of Juno’s new 195,000-square-foot offices.
Client(s) Sloan Kettering Institute and Juno Therapeutics, a Bristol Myers Squibb company On behalf of patentee Sloan Kettering Institute and exclusive licensee Juno Therapeutics (a subsidiary of Celgene Corporation, a Bristol Myers Squibb company), Jones Day and co-counsel prevailed in a jury trial that spanned eight days and involved 22 witnesses, wherein the jury awarded our clients $752 million in compensation for the infringement of their patents by Kite Pharma, Inc. (a Gilead Sciences ...
